Latest news with #AmericanDepositaryReceipts
Yahoo
3 days ago
- Business
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Why Genmab Stock Smashed It on Monday
The company's uterine cancer drug is advancing in its development. Management is also assertively conducting a share buyback program. 10 stocks we like better than Genmab A/s › On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (NASDAQ: GMAB), on the back of encouraging news from the laboratory. Management's disclosure of the status of a shareholder-pleasing initiative also helped boost sentiment. The price of those ADRs rose by almost 4% as a result -- quite a distance higher than the S&P 500's (SNPINDEX: ^GSPC) 0.4% advance. On Monday morning, Genmab announced a set of phase 1/2 clinical trial results for its rinatabart sesutecan (Rina-S) drug, which it's developing for a type of uterine cancer. The company said the drug showed a confirmed objective response rate of 50% in patients with an advanced form of the cancer who had received treatment with other medications. In its press release detailing the results, Genmab quoted study investigator Ira Winer as saying that the results "demonstrate encouraging data with Rina-S in this patient population and support its further development as a potential therapy for patients with advanced and recurrent endometrial cancer." The company added that, with this at its back, it aims to continue the development of the drug. Separately, Genmab updated investors about its current share buyback program, which authorized the repurchase of up to 2.2 million shares of its Europe-listed stock by July 10 of this year. The company was quite an aggressive buyer, snapping up just under 2.08 million shares for a total of slightly more than 2.7 billion Danish kronor ($411 million). Taken together, those two news items suggest that Genmab is on the right path with its development activities, and believes in its pipeline. The proof with Rina-S, of course, will come with later-stage clinical trials. However, at this point, the company's future looks promising, and the bullish market reaction feels justified. Before you buy stock in Genmab A/s, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Genmab A/s wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Genmab A/s. The Motley Fool has a disclosure policy. Why Genmab Stock Smashed It on Monday was originally published by The Motley Fool
Yahoo
28-05-2025
- Business
- Yahoo
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today
The company released its first-quarter results. Although it beat on earnings, it whiffed on revenue. 10 stocks we like better than Kingsoft Cloud › China's Kingsoft Cloud Holdings (NASDAQ: KC) was under something of a cloud with investors on Wednesday. They traded out of the niche tech company's U.S.-listed American Depositary Receipts (ADRs) after the release of its first-quarter results, leaving the securities with an almost 8% decline in price at market close. That was a far steeper drop than the S&P 500's (SNPINDEX: ^GSPC) 0.6%. For the quarter, Kingsoft Cloud came in at 1.97 billion yuan ($274 million), a nearly 11% increase from the same period of 2024. Management attributed this to higher take from the business of top Chinese tech company Xiaomi and that from artificial intelligence (AI) consumers, among other factors. However, the company still landed rather deeply in the red. Its net loss was nearly 314 million yuan ($44 million) against the year-ago deficit of 359 million yuan ($50 million). On a per-ADR basis, it only managed to trim the shortfall to 0.08 yuan ($0.01), versus first quarter 2024's loss of 0.10 yuan ($0.01). At least that net loss was narrower than expected, as analysts tracking Kingsoft Cloud stock were modeling a far steeper per-ADR figure of 0.62 yuan ($0.09). However, they were also anticipating higher revenue of 2.03 billion ($282 million). In its earnings release, management touted the emergence of AI technology and its effect on the company's fundamentals. It pointed out that billing for AI services increased by 228% on a year-over-year basis (to 525 million yuan, or $73 million). That accounted for 39% of the company's draw from public cloud services. With that kind of potential, I'd imagine that many Kingsoft Cloud investors are growing impatient for their company to drag itself out of the red on the bottom line, as it continues to consistently post bottom-line losses. Like many of them, personally, I'd stay away from the stock until those numbers start to meaningfully improve. Before you buy stock in Kingsoft Cloud, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Kingsoft Cloud wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,389!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $830,492!* Now, it's worth noting Stock Advisor's total average return is 982% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Xiaomi. The Motley Fool has a disclosure policy. Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News18
12-05-2025
- Business
- News18
Yes Bank Shares Jump 8% On Monday After SMBC Buys 20% Stake In Lender
Reported By : Last Updated: May 12, 2025, 09:34 IST Yes Bank Share Price: Shares in focus after Sumitomo Mitsui acquires 20% stake. Yes Bank Share Price, Yes Bank Stake Sale: Yes Bank Limited's shares jumped 8% in the opening session followed by Sumitomo Mitsui Banking Corporation (SMBC) acquired 20% stake in private lender following entering into a definitive agreement on May 09, 2025. The scrip opened at Rs 21.70 on Monday, against the previous day close at Rs 20.02 per equity. The scrip was trading at Rs 20.68 per equity with a gain of 3.25 per cent around 9:30 am. Yes Bank Stake Sale As per the agreement, SMBC bought 13.9 per cent stake from SBI via secondary stake purchase and 6.81 per cent aggregate stake from other bank shareholders including Axis Bank Limited, Bandhan Bank Limited, Federal Bank Limited, HDFC Bank Limited, ICICI Bank Limited, IDFC First Bank Limited, and Kotak Mahindra Bank Limited. SBI and the seven Investor Banks had invested in the Bank as part of the YES Bank Reconstruction Scheme in March 2020. SMBC, is a wholly owned subsidiary of Sumitomo Mitsui Financial Group, Inc. ('SMFG"). SMFG is the second largest banking group in Japan with Total Assets of ~US$2tn as of December 2024 with strong global presence. SMFG is listed on the Tokyo Stock Exchange, Premier Market of the Nagoya Stock Exchange and SMFG's American Depositary Receipts (ADRs) are also listed on the New York Stock Exchange. SMFG is rated A1 / A- (Stable) by Moody's and S&P respectively (long-term outlook). Swipe Left For Next Video View all SMBC is among the leading foreign banks in India and SMFG's wholly owned subsidiary, SMFG India Credit Company Limited, is among the largest diversified NBFCs in India. Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. Stay updated with all the latest news on the Stock Market, including market trends, Sensex and Nifty updates, top gainers and losers, and expert analysis. Get real-time insights, financial reports, and investment strategies—only on News18.
